#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ischaemic stroke Hereditary haemorrhagic telangiectasia Ehlers-Danlos syndrome Malignant peritoneal neoplasm Activated PI3 kinase delta syndrome Inflammatory myofibroblastic tumour Short stature Vitamin B12 deficiency Peripheral T-cell lymphoma unspecified Scleroderma associated digital ulcer Epileptic encephalopathy Haemophilia Acute graft versus host disease Plasma cell myeloma Pleomorphic leiomyosarcoma More trials…

    Learn about Rare Diseases

    Haemophilia A without inhibitors – Diagnostics Netherton’s syndrome – Treatment Lymphangiosarcoma Cystic fibrosis lung Haemophagocytic lymphohistiocytosis – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Basic Information Netherton’s syndrome Mucopolysaccharidosis Pulmonary fibrosis Glycogen storage disease type V – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ciclosporin A Progesterone FIBRIN Sar442970 Ibrutinib Kbp-336 ALXN2420 Daratumumab Tigulixostat Leniolisib Phosphate Ritonavir Morf-057 Trientine Dihydrochloride Cebsulfase Alfa Canakinumab RO7284755 RO7268489 HRS 9531 AZD1163 Pegvaliase More therapies…

    Learn about Your Condition

    Osteoporosis postmenopausal Vulval cancer recurrent Coronary artery occlusion Mucopolysaccharidosis Endometriosis Hepatitis alcoholic Head and neck cancer stage IV Trisomy 21 Immune-mediated enterocolitis Mast cell activation syndrome Critical illness Embolism venous Acute respiratory failure Hyperkalaemia Mantle cell lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    • Fluorescein Sodium
    Austria Croatia Czechia Denmark France Hungary +4

  • Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    France Germany Italy Poland Spain

  • Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Rituximab
    • Temozolomide
    Austria Belgium Czechia France Germany Italy +2

  • AUR200 for Patients with Generalized Myasthenia Gravis

    Recruiting

    1 1 1
    Investigated Drugs:
    • AUR200
    • Sodium Chloride
    Poland

  • Long-Term Safety and Efficacy of KL1333 in Adults with Primary Mitochondrial Disease

    Recruiting

    2 1 1
    Investigated Drugs:
    • 2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione
    Belgium Czechia Denmark France Germany Italy +1

  • VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • VMX-C001
    Austria Belgium Bulgaria Czechia Estonia France +9
Previous Page
1 … 639 640 641 642 643 … 1,655
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!